For his research on the development of rare malignant tumors in the hereditary DICER1 tumor predisposition syndrome, Dr. Felix Kommoss has been awarded the Rudolf Virchow Prize of the German Society of Pathology. Dr. Kommoss conducts research at the Heidelberg Faculty of Medicine at Heidelberg University and serves as Senior Physician and Head of Gynecologic Pathology at the Institute of Pathology, Heidelberg University Hospital.

The two inter-university funding programs SEED4EU+ and 4EU+ Visiting Professorships are entering a new round of calls. With these programs, the 4EU+ European University Alliance pursues the goal of strengthening links between the eight partner universities, giving scope to new ideas and supporting inter-university projects.

Four doctoral candidates from Heidelberg University have the opportunity to exchange ideas with outstanding scientists. They are set to take part in the 75th Lindau Nobel Laureate Meeting, which is being held in Lindau from 28 June to 3 July 2026. Jana Braunger, Tim Schubert, Laura Rueda Gensini and Nathan Trausch are among around 600 young researchers who have been selected for their outstanding academic achievements.

Prof. Dr Fred Hamprecht from the Interdisciplinary Center for Scientific Computing of Heidelberg University is receiving valuable funding from the ERC, which will support a project in the field of computational quantum chemistry. An ERC Advanced Grant also goes to Prof. Dr Andreas Meyer-Lindenberg, Director of the Central Institute of Mental Health and professor at the Medical Faculty Mannheim of Ruperto Carola.

In order to further strengthen Heidelberg University as an internationally recognized location of infection research, Prof. Dr Mathias Lichterfeld has been selected for an Alexander von Humboldt Professorship endowed with 7.8 million euros. Leading international academics are granted this most valuable of German research awards to enable them to conduct long-term, cutting-edge research at German universities.

For the first time in 14 years, there has been a change at the top of the hospital rankings, which are published annually by the MINQ Institute in collaboration with Stern. In its very first year of existence, the Heidelberg and Mannheim University Hospitals Consortium has taken first place.

Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide.

Researchers at Heidelberg Faculty of Medicine at Heidelberg University, in collaboration with partners from 29 German study centers, have found evidence of a potential biomarker for personalized therapy of acute myeloid leukemia (AML) in a Phase II study. Analyses showed that certain patients could benefit from additional treatment with the drug Motixafortide in addition to standard chemotherapy.

The German Research Foundation (DFG) funds continuation of Research Training Group (RTG) 2727 “Checkpoints of Innate Immunity in Cancer and Tissue Damage”, with around €5,8 million.

How do antimetabolite cancer drugs damage the genetic material of malignantly transformed cells and thereby destroy them? How might these drugs be used more precisely, particularly in the treatment of pediatric tumors? A new research group led by Dr. Christopher Carnie, a scientist at the Heidelberg Faculty of Medicine at Heidelberg University, will address these questions.

The German Research Foundation (DFG) is establishing new Collaborative Research Centres and extending existing research networks. Several DZHK sites are also involved. Particular emphasis is being placed on new research approaches to inflammation and thrombosis.

Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.

Different types of bone marrow stem cells give rise to blood and immune cells. A team led by Simon Haas now reports in ​“Nature Cell Biology” how that diversity develops. The findings could help improve stem cell therapies, including treatments for blood cancers.

Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the mechanisms underlying chronic pain be translated into new therapeutic approaches? These questions have been at the core of Rohini Kuner’s research for many years.

Research jointly led by scientists at the Heidelberg site of the German Center for Lung Research and investigators in Boston at Massachusetts General Hospital and Harvard Medical School identifies a new immunotherapy-based approach for lung fibrosis: reactivating natural killer cell (NK cells) to eliminate senescent fibroblasts, reverse scarring and restore the lung’s ability to heal.

The Collaborative Research Centre (CRC) 1550 “Molecular Circuits of Heart Disease” at Heidelberg University is entering its second funding period. The German Research Foundation (DFG) has approved approximately EUR 17.4 million in funding for the next four years. The spokesperson is Johannes Backs, Professor of Experimental Cardiology at the Heidelberg Faculty of Medicine.

From May 15–16, 2026, the 3rd International Symposium “Frontiers in Skin Immunity” will bring leading experts in dermatology and immunology to Heidelberg. Organized by the SFB Transregio 156 “The Skin as Sensor and Initiator of Local and Systemic Immunity” and the Medical Faculty of Heidelberg University the meeting highlights advances in understanding skin immune responses and marks the conclusion of the consortium’s third funding period.

Her ground-breaking research studies on the regulation of gene activity have earned Dr Angelika Feldmann the Hella Bühler Prize for 2026, which is endowed with 100,000 euros.

Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San Francisco (USA), an international research team has evaluated a novel approach for the diagnosis of pulmonary tuberculosis. The method enables detection of Mycobacterium tuberculosis without laboratory infrastructure, within a markedly shorter time frame than conventional diagnostics, and using a simple swab.

Brain metastases are among the most serious complications of breast cancer. Researchers at Heidelberg University, DKFZ, and UKHD have concluded an investigation of the immune cells in the brain tissue surrounding these breast cancer brain metastases. Their findings: spatial distribution patterns of immune cells are associated with prolonged patient survival. These findings could help to guide use of immunotherapies for breast cancer patients.

Europe’s dependence on fossil fuels is not only making the continent economically and politically vulnerable, it also has consequences for the population’s health. Growing air pollution, heat damage and the climate-related spread of infectious diseases are looming, warns the 2026 Europe Report of the Lancet Countdown on Health and Climate Change, which its co-directors are about to present to the public.

In the earliest phase of creating human proteins, the protein complex NAC performs an essential task by starting the first steps towards folding proteins into their correct three-dimensional structures. This discovery was made by an international research team led by scientists from the Center for Molecular Biology of Heidelberg University.

Immunotherapies have greatly improved the treatment of metastatic melanoma, but they can cause serious side effects. A study led by researchers from Heidelberg University's Medical Faculty, the Heidelberg University Hospital, and the NCT in Heidelberg now shows that autoantibodies detected in the blood before the start of therapy could help to better assess the individual risk of side effects in patients.

Protein activity can be precisely regulated via subtle changes in temperature using heat-sensitive switches. Underlying this capability is a novel modular design strategy developed by researchers at the Institute of Pharmacy and Molecular Biotechnology of Heidelberg University. The strategy allows the integration of sensory domains in various proteins regardless of function or spatial structure.

New findings indicate that a shingles vaccination could not only reduce the risk of cognitive impairment and dementia, but also reduce disease progression among those living with dementia.